Establishment Labs Holdings Inc

Establishment Labs Holdings, Inc. is a technology company, which engages in the design, development, manufacture, and marketing of silicone breast implants. It generates income from customers in Europe, the Middle East, Latin America, and Asia. The firm's products include Motiva Implants, Motiva Flora Tissue Expander, Motiva Ergonomix, and Motiva Ergonomix2. The company was founded by Juan Jose Chacon-Quiros in 2004 and is headquartered in Alajuela, Costa Rica.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Establishment Labs posts strong revenue growth and sets ambitious targets

Establishment Labs reported strong revenue growth in Q4 2022 and outlined ambitious revenue guidance for 2023, supported by strategic product launches and market expansion initiatives.
While facing challenges in managing expenses and optimizing margins, the company's focus on growth opportunities and market transformation positions it for long-term success and achieving its revenue targets.
With a solid cash position, investments in new facilities, and a clear roadmap for future growth, Establishment Labs demonstrates resilience and strategic foresight in navigating the competitive landscape.

Establishment Labs (ESTA) reports robust Q1 revenue growth and global expansion

Establishment Labs Holdings Inc (ESTA) delivered strong revenue growth and strategic advancements in Q1 2023, positioning the company for future success.
While facing challenges in managing expenses and entering new markets, the company's focus on innovation and global expansion presents promising opportunities.
With a solid financial foundation and a clear growth strategy, ESTA is poised to capitalize on market demand and drive sustainable growth in the coming quarters.

Establishment Labs Holdings Inc reports strong Q2 growth and eyes expansion in China and Europe

Establishment Labs Holdings Inc's Q2 2023 performance showcased revenue growth and strategic advancements, despite challenges in profitability margins.
The company's focus on expanding into new markets, launching innovative products, and strengthening partnerships presents promising growth opportunities.
Maintaining revenue guidance, preparing for new launches, and addressing operational challenges position the company for a strong finish to 2023.

Establishment Labs maintains revenue amid global slowdown, eyes future growth

Establishment Labs faces challenges from a global slowdown in aesthetics procedures but sees opportunities in new markets and innovative products.
The company's focus on cost control and cash preservation aligns with expectations of positive EBITDA and cash flow in the future.
Key strengths include FDA clearances, positive study outcomes, and confidence in growth prospects beyond 2023.

Establishment Labs (ESTA) reports robust Q4 revenue and eyes global expansion

Establishment Labs Holdings Inc (ESTA) demonstrated strong revenue growth and cost management in Q4 2023.
The company faces challenges in gross profit and cash utilization but is poised for improved margins and profitability in 2024 and beyond.
Opportunities lie in global expansion, market penetration with innovative products, and a focus on achieving positive cash flow in the near future.

Establishment Labs reports strong Q1 revenue and eyes global growth

Establishment Labs Holdings Inc showed strong Q1 performance with revenue of $37.2 million.
The company aims to achieve positive adjusted EBITDA by end of 2024 and positive cash flow by end of 2025.
Progress in FDA approvals, market diversification, and strategic expansion plans are key strengths.
Challenges include addressing net losses, achieving positive EBITDA, and upcoming FDA inspection.

Establishment Labs Holdings Inc reports strong Q2 performance and eyes U.S. and China growth

Establishment Labs Holdings Inc demonstrated strong revenue growth and progress towards profitability in Q2 2024.
While facing challenges in Latin America, the company is capitalizing on opportunities in the U.S. and China markets.
With a focus on new product launches and improving gross margins, the company is poised for future growth and financial stability.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, today announced financial results for the fourth quarter and full year ended December 31, 2023 and provided 2024 guidance. Fourth Quarter Highlights and Outlook 2024 revenue guidance of $174 million to $184 million, an increase of 5% to 11% over 2023. Guidance does not include reve.

Establishment Labs Reports Fourth Quarter and Full Year 2023 Financial Results and Provides 2024 Guidance

NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a medical technology company focused on women's health, initially in the breast aesthetics and reconstruction market, today announced that it has amended its $225 million term loan facility with funds managed by Oaktree Capital Management, L.P. (“Oaktree”). The terms on the two tranches already drawn under the facility, which total $175 million, are unchanged. The remaining two $25 million tranches are amended as follow.

Establishment Labs Announces Amended Credit Facility with Oaktree

Establishment Labs Holdings Inc. (ESTA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate Establishment Labs Holdings Inc. (ESTA) to Report a Decline in Earnings: What to Look Out for

NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, plans to announce its financial results for the quarter ended December 31, 2023, after the market closes on Wednesday, February 28, 2024, and will host a conference call at 4:30 pm ET that day to discuss those results. To participate in the conference call, dial (877) 407-8037 (U.S.

Establishment Labs to Announce Fourth Quarter 2023 Financial Results on February 28

NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, today announced it has launched Motiva® Implants in China. “China is the second largest market globally, but has the opportunity to be much larger,” commented Juan José Chacón-Quirós, Establishment Labs Founder and Chief Executive Officer. “Establishment Labs was founded to make pr.

Establishment Labs Announces Commercial Launch of Motiva Implants in China

NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA) (“Establishment Labs” or the “Company”), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, today announced it has entered into a securities purchase agreement with select institutional accredited investors to purchase common shares of the Company, or pre-funded warrants in lieu thereof. The Company also announced preliminary unaudi.

Establishment Labs Announces $50 Million Private Placement and Preliminary Unaudited Financial Results for the Fourth Quarter and Fiscal Year 2023

NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, announced that the Motiva Flora® SmoothSilk® Tissue Expander was used for the first time in the United States at the University of Texas MD Anderson Cancer Center in Houston by Mark Clemens, MD MBA FACS, Professor of Plastic Surgery. The recent FDA clearance and first procedure mar.

Establishment Labs Announces First U.S. Commercial Procedure with Motiva Flora Tissue Expander

NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, today announced that Juan José Chacón-Quirós, Founder and Chief Executive Officer, and Raj Denhoy, Chief Financial Officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024 at 2:15 p.m. Pacific Time. A live webcast of the presentation.

Establishment Labs to Present at the 42nd Annual J.P. Morgan Healthcare Conference

NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, today announced it has received National Medical Products Administration (NMPA) approval in China for Motiva® Implants. “Our approval in China marks Establishment Labs' entry into the second largest global and most dynamic market for breast aesthetics in the world,” said Juan José.

Establishment Labs Announces National Medical Products Administration Approval for Motiva Implants in China

Establishment Labs missed consensus revenue and earnings estimates in Q3. The company also slashed its full-year guidance.

Why Establishment Labs Stock Is Crashing Today

Establishment Labs Holdings Inc. (NASDAQ:ESTA ) Q3 2023 Earnings Conference Call November 7, 2023 4:30 PM ET Company Participants Juan Jose Chacon Quiros - Founder and Chief Executive Officer Raj Denhoy - Chief Financial Officer Conference Call Participants Mike Sarcone - Jefferies Allen Gong - JPMorgan Anthony Petrone - Mizuho Group Josh Jennings - TD Cowen Neil Chatterji - B. Riley Joanne Wuensch - Citibank Sam Eiber - BTIG George Sellers - Stephens Operator Good afternoon.

Establishment Labs Holdings Inc. (ESTA) Q3 2023 Earnings Call Transcript

Establishment Labs Holdings Inc. (ESTA) came out with a quarterly loss of $1.12 per share versus the Zacks Consensus Estimate of a loss of $0.72. This compares to loss of $0.76 per share a year ago.

Establishment Labs Holdings Inc. (ESTA) Reports Q3 Loss, Lags Revenue Estimates

NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, today announced financial results for the third quarter ended September 30, 2023. Third Quarter Highlights and Outlook Third quarter worldwide revenue of $38.5 million increased 0.8% year-over-year. 2023 revenue guidance updated to approximately $165 million, an increase of 2% over.

Establishment Labs Reports Third Quarter 2023 Financial Results

Establishment Labs Holdings Inc. (ESTA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

Establishment Labs Holdings Inc. (ESTA) Soars 7.8%: Is Further Upside Left in the Stock?

Establishment Labs Holdings Inc. (ESTA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Establishment Labs Holdings Inc. (ESTA) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, plans to announce its financial results for the quarter ended Semptember 30, 2023, after the market closes on Tuesday, November 7, 2023, and will host a conference call at 4:30 pm ET that day to discuss those results. To participate in the conference call, dial (877) 407-8037 (U.S.

Establishment Labs to Announce Third Quarter 2023 Financial Results on November 7

Establishment Labs Holdings Inc. (ESTA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

Strength Seen in Establishment Labs Holdings Inc. (ESTA): Can Its 14.3% Jump Turn into More Strength?

NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the Motiva Flora® SmoothSilk® Tissue Expander. The Flora® SmoothSilk® Tissue Expander offers several proprietary innovations, including Establishment Labs' patented SmoothSilk® surface techn.

Establishment Labs Announces FDA Clearance of Motiva Flora SmoothSilk Tissue Expander

NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, announced today both the two-year clinical results of Mia Femtech™ as well as its launch of Zen™, the Company's next generation RFID technology, at the 8th Annual World Symposium on Ergonomic Implants (WSEI) being held this week in Lisbon, Portugal. The Mia Feasibility Clinical Stu.

Establishment Labs Announces Two-Year Mia Femtech Clinical Results and the Launch of Zen at 8th World Symposium on Ergonomic Implants

Establishment Labs Holdings Inc. (NASDAQ:ESTA ) Q2 2023 Earnings Conference Call August 8, 2023 4:30 PM ET Company Participants Raj Denhoy - Chief Financial Officer Juan José Chacón-Quirós - Chief Executive Officer Conference Call Participants Young Li - Jefferies Anthony Petrone - Mizuho Group Josh Jennings - Cowen & Company Sam Eiber - BTIG Neil Chatterji - B. Riley George Sellers - Stephens Operator Good afternoon.

Establishment Labs Holdings Inc. (ESTA) Q2 2023 Earnings Call Transcript

NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, today announced financial results for the second quarter ended June 30, 2023. First Quarter Highlights and Outlook Second quarter worldwide revenue of $48.6 million increased 18.0% year-over-year and was a new quarterly record. 2023 revenue guidance remains $200 million to $210 mil.

Establishment Labs Reports Record Second Quarter 2023 Financial Results

NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, plans to announce its financial results for the quarter ended June 30, 2023, after the market closes on Tuesday, August 8, 2023, and will host a conference call at 4:30 pm ET that day to discuss those results. To participate in the conference call, dial (877) 407-8037 (U.S. and Can.

Establishment Labs to Announce Second Quarter 2023 Financial Results on August 8

NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, today announced the grand opening of the Sulàyöm Innovation Campus in the Coyol Free Zone, Costa Rica. The Sulàyöm Campus will support Establishment Labs' continued global growth with additional capacity and capabilities in manufacturing, R&D, digital media, training, and medic.

Establishment Labs Celebrates Opening of Sulàyöm Innovation Campus and Outlines New and Expanded Capabilities

NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, today announced its participation in two upcoming investor conferences. Juan José Chacón-Quirós, Chief Executive Officer and Founder, and Raj Denhoy, Chief Financial Officer, will participate in the 2023 Jefferies Healthcare Conference held June 7-9, 2023. Mr. Chacón-Quirós and Mr.

Establishment Labs to Participate in Two Upcoming Investor Conferences

NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, today announced it has received CE marking under the European Medical Device Regulation for the Motiva Injector®, the Motiva® Inflatable Balloon, and the Motiva® Channel Dissector. “The approval in Europe of our minimally invasive tools is an important step in the evolution of plas.

News for Establishment Labs Holdings Inc Stock (ESTA)